Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
14.61
-0.16 (-1.05%)
Nov 5, 2024, 11:12 AM EST - Market open
Zymeworks Employees
As of December 31, 2023, Zymeworks had 278 total employees, including 272 full-time and 6 part-time employees. The number of employees decreased by 16 or -5.44% compared to the previous year.
Employees
278
Change (1Y)
-16
Growth (1Y)
-5.44%
Revenue / Employee
$223,737
Profits / Employee
-$408,888
Market Cap
1.01B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Phibro Animal Health | 1,940 |
Castle Biosciences | 610 |
Autolus Therapeutics | 471 |
Prothena Corporation | 173 |
Liquidia | 145 |
CARGO Therapeutics | 116 |
Cullinan Therapeutics | 85 |
Pulse Biosciences | 56 |
ZYME News
- 5 hours ago - Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors - GlobeNewsWire
- 1 day ago - Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab - Seeking Alpha
- 4 days ago - Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 11 days ago - Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference - GlobeNewsWire
- 15 days ago - Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers - GlobeNewsWire
- 26 days ago - Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024 - GlobeNewsWire
- 5 weeks ago - Zymeworks Approaching A Moment Of Truth With Zanidatamab - Seeking Alpha